APA (7th ed.) Citation

Rascol, O., Tönges, L., deVries, T., Jaros, M., Quartel, A., Jacobs, D., & groups, A. I. a. A. I. s. (2022). Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism & Related Disorders, 96, 65. https://doi.org/10.1016/j.parkreldis.2022.01.022

Chicago Style (17th ed.) Citation

Rascol, Olivier, Lars Tönges, Tina deVries, Mark Jaros, Adrian Quartel, David Jacobs, and ALLAY-LID I and ALLAY-LID II study groups. "Immediate-release/extended-release Amantadine (OS320) to Treat Parkinson's Disease with Levodopa-induced Dyskinesia: Analysis of the Randomized, Controlled ALLAY-LID Studies." Parkinsonism & Related Disorders 96 (2022): 65. https://doi.org/10.1016/j.parkreldis.2022.01.022.

MLA (9th ed.) Citation

Rascol, Olivier, et al. "Immediate-release/extended-release Amantadine (OS320) to Treat Parkinson's Disease with Levodopa-induced Dyskinesia: Analysis of the Randomized, Controlled ALLAY-LID Studies." Parkinsonism & Related Disorders, vol. 96, 2022, p. 65, https://doi.org/10.1016/j.parkreldis.2022.01.022.